ALKERMES | ALKS - Passività Correnti





Passività Correnti Cambiamento Data
AbbVie USD 43.1B 1.46B 2026-09
Acadia Pharmaceuticals USD 332.22M 29.22M 2026-09
ALKERMES USD 651.93M 10.16M 2026-09
Amgen USD 23.23B 2.27B 2026-09
Biogen USD 3.9B 18.7M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Coherus Biosciences USD 75.51M 56.82M 2026-06
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
Heron Therapeutics USD 89.85M 2.3M 2026-09
Ionis Pharmaceuticals USD 435.29M 119.65M 2026-09
J&J USD 55.46B 562M 2026-09
Malin Corporation EUR 1000K 500K 2024-12
Merck USD 28.8B 1.07B 2026-09
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Otsuka Holdings JPY 701.98B 36.98B 2026-09
Ovoca Bio EUR 1.3M 1.11M 2025-12
Pfizer USD 31.73B 920M 2026-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Vertex Pharmaceuticals USD 5B 1.06B 2026-09